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Figure 2. COMP value in ACL, Normal and OA groups.
and ACL patients (p<0.01). There was no signiﬁcant difference in
CS846 levels between ACL patients and those who were healthy
(p=0.18). Likewise, COMP levels were signiﬁcantly higher in OA
patients vs. healthy and ACL patients (p<0.04). Again, there was
no signiﬁcant difference in COMP levels between ACL patients
and those who were healthy (p=0.95).
Conclusions: In this study, CS846 and COMP markers were
signiﬁcantly higher in knee OA patients than ACL patients and
healthy volunteers suggesting that OA patients are undergoing
more cartilage degeneration and attempt at cartilage repair than
the other groups. The lack of signiﬁcant differences between the
ACL and healthy groups may reﬂect the young age of the ACL
patients, the relatively short time since injury (average 3.4 yrs) or
perhaps the time dependent nature of attempted cartilage repair.
In addition, because these values are systemic and not localized
to the knee, lower average values may reﬂect overall generally
healthy cartilage which may mask higher levels at the site of
injury.
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THE EFFECT OF DISEASE-MODIFYING ANTI-
RHEUMATIC DRUGS ON COX-2 IN CHONDROCYTES.
AUROTHIOMALATE INHIBITS MAP KINASE ACTIVATION,
PGE2PRODUCTION AND COX-2 EXPRESSION
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Purpose: Disease-modifying anti-rheumatic drugs (DMARDs)
suppress inﬂammation, and retard cartilage degradation and
bone erosion in arthritis. The molecular mechanisms of action
of many traditional DMARDs are not known in detail. Their
effects on macrophages and synovial cells have been inves-
tigated but very little is known on their effects on cartilage
and inﬂammatory factors produced by affected chondrocytes.
Inducible prostaglandin synthase (cyclooxygenase-2, COX-2) is
expressed in rheumatoid and osteoarthritic cartilage and pro-
duces high amounts of proinﬂammatory prostanoids in the joint.
Mitogen-activated protein kinases (MAPKs) are a family of ser-
ine/threonine kinases that mediate inﬂammatory and other extra-
cellular signals to intracellular target proteins, e.g. transcription
factors that regulate gene expression. In the present study, we
investigated the effects of different DMARDs on interleukin-1β
(IL-1β) -induced COX-2 expression and further, aurothiomalate’s
effects and mechanisms of action in chondrocyte cultures and in
human cartilage in more detail.
Methods: Cartilage tissue was obtained from the leftover pieces
of total knee replacement surgery from patients with OA. Im-
mortalized H4 murine chondrocytes* were used in cell culture
experiments.
Results: In the present study, we investigated the effects of tra-
ditional DMARDs on COX-2 expression in chondrocytes. Unlike
the other tested compounds (cyclosporin A, hydroxychloroquine,
leﬂunomide, its active metabolite A771726, methotrexate and
sulfasalazine), aurothiomalate was found to be effective at clini-
cally relevant drug concentrations. Aurothiomalate inhibited IL-1β
-induced prostaglandin E2(PGE2) production in chondrocytes
and in human cartilage. Aurothiomalate inhibited also COX-2
expression by destabilizing its mRNA as did p38 MAPK inhibitor
SB203580. Interestingly, aurothiomalate inhibited the phospho-
rylation of JNK and p38 MAPKs, which may well explain its
inhibitory effect on COX-2 expression and PGE2 production in
chondrocytes.
Conclusions: The results provide a novel mechanism for the
anti-inﬂammatory action of aurothiomalate through reduced p38
and JNK MAPK activation and COX-2 expression, and stress
chondrocytes and their products as important targets in drug
development for arthritis.
*Murine H4 chondrocyte cell line was kindly provided by Peter
van der Kraan from Laboratory of Experimental Rheumatology,
University Medical Center Nijmegen, The Netherlands.
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Purpose and aim: Nitric oxide (NO) is an important mediator
of inﬂammation and joint destruction in rheumatoid arthritis (RA)
and osteoarthritis (OA). Oxygen reactive species induced by
NO can transform tyrosine residues of joint tissue proteins into
nitrosylated modiﬁed forms. An ELISA recognizing speciﬁcally
degradation fragments of the nitrosylated-modiﬁed telopeptide
(IIINys) of type III collagen -an abundant protein of synovial
tissue- has been developed and increased circulating IIINys
levels were found in patients with active RA. However, the tissue
origin of IIINys was not determined and no data in OA has yet
been reported. The aim of this study was to investigate whether
type III collagen nitrosylation can be detected in the synovial
tissue of patients with OA and RA and be reﬂected by changes
in synovial ﬂuid and circulating IIINys levels.
Methods: Synovial tissue of the knee joint was obtained from
patients with knee OA (n= 4), patients with RA (n=5) and non-
arthritic controls (n = 2) during joint replacement. Levels of IIINys
were measured by ELISA in knee joint ﬂuid and paired plasma
samples from 11 patients with knee OA and 11 patients with
active RA. We also measured circulating IIINys levels in 89
patients with painful knee OA (79% women; mean age 63.0;
mean disease duration 6.1 years, radiological Kellgren-Lawrence
score II or III), 55 patients with active RA (65% female, mean
age: 55 years, mean disease duration 14 years) and 83 healthy
women and men (20 to 60 yrs of age)
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Results: Immunohistochemistry of OA and RA synovial tissue
showed strong IIINys staining in the ﬁbrous tissue surrounding
synoviocytes, with additional localization around lymphoid cells
in RA sections, whereas no immunoreactivity could be detected
in control tissue specimens.
Patient group IIINys, ng/ml; Ratio joint ﬂuid/plasma
median (range) IIINys level;
median (range)Knee joint ﬂuid Paired Plasma
OA (n=11) 6.61 (1.16-9.77) 23.6 (8.6-40.7)# 0.24 (0.04-0.81)
RA (n=11) 31.3 (0.6-84.4)* 61.6 (48.4-5.4)*# 0.44 (0.01-1.31)
* p<0.01 vs corresponding ﬂuids from patients with OA; # p<0.01
vs paired joint ﬂuid
As shown on the table, both in joint ﬂuid and plasma, IIINys
levels were signiﬁcantly higher in patients with RA than in OA
individuals. Plasma IIINys levels were signiﬁcantly higher than
paired joint ﬂuid values in both OA and RA patients, as shown by
a ratio (joint ﬂuid/serum) <1. There was a signiﬁcant correlation
between knee joint ﬂuid and paired plasma IIINys levels (r = 0.64,
p=0.0034). Compared to healthy sex and age-matched controls,
circulating IIINys levels were increased by a median of 43% in
89 patients with knee OA (p <0.0001) and by 216% (p<0001) in
55 patients with active RA.
Conclusions: Type III collagen of synovial tissue from patients
with OA and RA is characterized by increased N-telopeptide
nitrosylation which can be detected by joint ﬂuid and circulating
IIINys levels. IIINys may be a useful biochemical marker of
NO-induced joint damage in OA and RA.
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Purpose: To use the collagenase cleavage site neoepitope,
TIINE, a marker of type II collagen degradation in articular
cartilage, to examine the basis for the observed slowing of JSN
in patients with knee OA treated with doxy in a 30-month RCT
[1].
Methods: The creatinine-adjusted urinary TIINE (uTIINE) con-
centration (inter-assay variability =8%) was determined at base-
line and every 6 months thereafter in a subset of subjects
from the RCT. The subset was selected a priori to permit com-
parison of 60 radiographic progressors with 60 radiographic
non-progressors, as deﬁned by JSN at 30 months in highly
standardized, semiﬂexed anteroposterior x-rays [2].
Results: At baseline, mean uTIINE levels were 109 ± 64 and
110 ± 68 in doxy-treated and placebo, respectively (p=NS). The
CV of uTIINE concentrations over the 6 placebo visits was 30%.
By 6 months, uTIINE levels had increased in the doxy group
by 40% relative to the placebo group and remained elevated
for the remainder of the treatment period. Over the 5 follow-up
visits, the mean uTIINE concentration for doxy subjects was 144
± 81 ng/mmol creatinine and that for the placebo group 115 ±
49 ng/mmol creatinine, p = 0.01). The difference between the
baseline uTIINE concentration for an individual subject and the
mean of the TIINE levels for that person over the treatment period
was even more signiﬁcant (p=0.001) than the mean difference
in uTIINE levels between treatment groups. In both treatment
groups, the correlation between TIINE levels and JSN in the
index knee was weak (for doxy, r2 = 0.06, p = 0.08; for placebo,
r2 =0.06, p = 0.05).
Conclusions: Several reports suggest doxy may limit collagen
breakdown in articular cartilage by inhibiting MMPs. The increase
in TIINE levels in patients treated with doxy strongly suggests
that inhibition of collagenase activity in knee articular cartilage
does not explain retardation of JSN in knees of patients treated
with doxy. These results are consistent with analyses of other
markers of Type II collagen catabolism performed on plasma
samples from this subset of OA patients, which showed that
neither the level of type II collagen C-telopeptide crosslink [3] nor
of C2C [4] had predictive or concurrent validity with respect to
JSN.
Several factors could account for the poor correlation between
marker levels and JSN in the OA knee, e.g., extra-articular
metabolism of Type II collagen or presence of OA in other joints.
Also, articular cartilage is not the sole determinant of joint space
width in a knee radiograph. A signiﬁcant proportion of the to-
tal decrease in interbone distance in the medial compartment
of patients with knee OA may be due to meniscal degenera-
tion/subluxation, rather than loss of hyaline articular cartilage.
Finally, inhibition by doxy of an enzyme involved in catabolism
of the TIINE epitope could increase the level of uTIINE inde-
pendent of a drug effect on MMP-mediated type II collagen
catabolism. The increase in uTIINE levels in OA patients treated
with doxy and the absence of a relation between JSN and levels
of markers of Type II collagen breakdown both strongly suggest
that the slowing of JSN in index knees of patients treated with
doxy can not be attributed to the inhibition of collagenase in OA
cartilage
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JOINT SPECIFIC CONCENTRATIONSOF BONE
ALKALINE PHOSPHATASE IN SYNOVIAL FLUIDS OF
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Purpose: Osteoblasts synthesize and secrete bone-speciﬁc al-
kaline phosphatase (BAP), a non-collagenous protein that has
been hypothesized to contribute to calciﬁcation of bone. Even
though the health of subchondral bone may be critical in the
development of osteoarthritis (OA), few studies have measured
bone-speciﬁc biomarkers to examine bone turnover associated
with OA. As a result of high-speed exercise, horses will com-
monly sustain injury to subchondral bone. This may result in
osteochondral (OC) fragmentation, exposing subchondral bone
to the synovial cavity. Therefore, OC injury in the horse is a
useful model to examine the relationship of concurrent injury to
bone and cartilage and the resulting development of OA. The
aim of the present study was to investigate whether there was a
joint speciﬁc difference in synovial ﬂuid (SF) BAP concentrations
in normal and OC injured joints of horses.
Methods: SF was collected from 37 joints of 34 Thoroughbred
racehorses undergoing arthroscopic surgery for removal of OC
fragments from either the carpal joints (n=18) or the metacarpo-
/metatarsophalangeal (MP) joints (n=19). SF was also obtained
